Significantly improve symptoms in Parkinson's disease patients with new mechanism therapy Phase 2 clinical results are positive

Today, Cerevance announced that its potential "first-in-class" oral Parkinson's disease investigational therapy CVN424 has achieved positive results in a Phase 2 clinical trial

Cerevance's drug discovery platform is based on a new technology called NETSseq, which can label and collect specific disease-related cell types from patient brain tissue, and then perform transcriptome and epigenetic analysis on them to discover based on this knowledge New targets for the treatment of central nervous system diseases

▲NETSseq technology platform (Image source: Cerevance's official website)

In this randomized, double-blind, placebo-controlled Phase 2 clinical trial, approximately 135 Parkinson's disease patients received two different doses of CVN424

Trial results showed that after 4 weeks of treatment, high-dose CVN424 improved the "OFF" period by 1.

References:

[1] Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism.